Megaclox Ampicillin and Dicloxacillin Capsules, 500 mg

  • Product Name : Megaclox Ampicillin and Dicloxacillin Capsules, 500 mg
  • Category : Antibiotic
  • Manufacturer Name : Cipla
  • Trade Name : Megaclox
  • Available Dosage : 20x10 Capsules
  • Packing : Strip
  • Pack Insert/Leaflet : 1 Pack/200 Capsules
  • Ingredients : Ampicillin, Dicloxacillin
  • Formulation : Capsule
  • Therapeutic use : to treat patients with bacterial infections
  • Production Capacity : 100000

Description:-

Introduction to Megaclox Ampicillin and Dicloxacillin Capsules, 500 mg

Megaclox, provided by Lexaro Healthcare, features a fixed-dose combination of Ampicillin and Dicloxacillin, each at 500 mg per capsule. This combination antibiotic leverages the strengths of Ampicillin, a broad-spectrum penicillin, and Dicloxacillin, a penicillinase-resistant penicillin, to offer comprehensive coverage against both gram-positive and gram-negative bacteria.


Uses of Megaclox Ampicillin and Dicloxacillin Capsules, 500 mg

Megaclox is primarily prescribed for:

Treating a variety of bacterial infections, including respiratory tract infections, urinary tract infections, and skin and soft tissue infections.

Managing infections caused by both penicillin-sensitive and penicillin-resistant bacteria.

Providing empirical therapy for serious infections where a broad-spectrum antibiotic is warranted.


Benefits of Megaclox Ampicillin and Dicloxacillin Capsules, 500 mg

Combines the antibacterial properties of Ampicillin and Dicloxacillin for a broad-spectrum effect.

Effective against a wide range of both gram-positive and gram-negative bacteria.

Offers protection against beta-lactamase-producing bacteria due to the presence of Dicloxacillin.

Provides a convenient oral dosage form for effective treatment of various infections.

Improves clinical outcomes with its dual-action antibacterial approach.


Mechanism of Action of Megaclox Ampicillin and Dicloxacillin Capsules, 500 mg

Ampicillin works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). This inhibition disrupts the cross-linking of peptidoglycan layers in the bacterial cell wall, leading to cell lysis and death.

Dicloxacillin is a penicillinase-resistant penicillin that also inhibits bacterial cell wall synthesis. It is effective against beta-lactamase-producing bacteria that would otherwise inactivate standard penicillins, thus extending the antibacterial activity of the combination.